MHRA Drug Safety Update

View as a webpage / Share

MHRA Banner 2025 logo

MHRA Drug Safety Update

December 2025


Mesalazine and idiopathic intracranial hypertension

Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products.


It's easy to report

Report a suspected adverse drug reaction online
or download the Yellow Card app

REPORT ONLINE


Thank you,

The Medicines and Healthcare products Regulatory Agency

MHRA TwitterMHRA FacebookMHRA LinkedInMHRA YouTubeMHRA Inspectorate blog